COR Cencora
Intrinsic value$130.45
Price (at call)$327.79
Margin of safety
-60.2%
vs market (rating basis)
-6.1%
Model unavailable; showing baseline valuation.
⚠ LLM error: empty response; using baseline
The story
Value drivers
| Revenue growth (Y1) | 10.4% |
| Terminal growth | 3.5% |
| Forecast horizon | 10y |
| Target operating margin | 1.2% |
| Years to target margin | 5 |
| Sales-to-capital | 5.00 |
| Beta | 0.57 |
| Failure probability | 0.0% |
| Cost of capital (WACC) | 6.9% |
| Terminal WACC | 8.6% |
Valuation bridge
| PV of explicit FCFF | -15.54B |
| PV of terminal value | 43.98B |
| Equity value | 24.89B |
| ÷ shares → per share | $130.45 |
News
neutral +0.10 · 8 articles
- McKesson Raises FY27 Guidance as Oncology and GLP-1 Growth Accelerate
- Is McKesson Stock Worth Buying as Growth Meets a Premium Valuation?
- AbbVie vs. Bristol-Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?
- Cencora (COR): Leveraging Healthcare Growth and AI-Driven Productivity
- 5 Insightful Analyst Questions From Cencora’s Q2 Earnings Call
- US Stock Market Today: S&P 500 Futures Edge Up As Traders Eye Key CPI
- US Equity Markets End Mixed Amid Tech Stock Gains, Lower Inflation Data
- Sector Update: Healthcare Stocks Advance Late Afternoon
Projected free cash flow to the firm
| Yr | Revenue | Growth | Margin | NOPAT | Reinvest | FCFF | PV |
|---|---|---|---|---|---|---|---|
| 1 | 367.49B | 10.4% | 1.2% | 3.16B | 6.94B | -3.79B | -3.54B |
| 2 | 403.01B | 9.7% | 1.2% | 3.46B | 7.10B | -3.64B | -3.18B |
| 3 | 438.85B | 8.9% | 1.2% | 3.77B | 7.17B | -3.40B | -2.78B |
| 4 | 474.49B | 8.1% | 1.2% | 4.08B | 7.13B | -3.05B | -2.34B |
| 5 | 509.38B | 7.4% | 1.2% | 4.38B | 6.98B | -2.60B | -1.86B |
| 6 | 542.90B | 6.6% | 1.2% | 4.66B | 6.71B | -2.04B | -1.37B |
| 7 | 574.45B | 5.8% | 1.2% | 4.94B | 6.31B | -1.37B | -860.60M |
| 8 | 603.41B | 5.0% | 1.2% | 5.18B | 5.79B | -607.39M | -355.65M |
| 9 | 629.18B | 4.3% | 1.2% | 5.41B | 5.15B | 251.84M | 137.92M |
| 10 | 651.20B | 3.5% | 1.2% | 5.59B | 4.40B | 1.19B | 609.75M |